Givastomig, a CLDN18.2 x 4-1BB bispecific antibody, continues to show robust efficacy when combined with nivolumab and ...

In patients with high PD-L1 expression identified before surgery, clinicians should consider the possibility of lymph node metastasis when determining surgical strategy, including the extent of lymph ...

The effect of PARP inhibition on androgen receptor localization and activity in castration resistant prostate cancer. This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I. This ...

The study of constructed αROR1‐CAR T cells showed an increase of PD-L1 expression when exposed to elevated pressure, driving resistance to CAR T cell-mediated cytotoxicity. However, the findings also ...

This study was led by Yi-Long Wu (Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital, Chinese Thoracic Oncology Group (CTONG)). In this open-label, phase 2 study (NCT04252365), ...

A Potential New Standard for First-Line HER2+ Advanced GEA* Combination therapy showed compelling survival and disease control compared to current standard, regardless of PD-L1 status* High GEA burden ...

Utilizing a >400 RFU threshold, treatment with leronlimab was associated with the upregulation of PD-L1 in CTCs and cancer-associated macrophage-like cells (CAMLs) in 76% (n=16/21) of patients overall ...

Investigators reported extended 5-year follow-up data from the CheckMate 274 trial including exploratory MIBC and circulating tumor (ct)DNA data.